People who lose a lot of weight, after bariatric surgery or, increasingly, on GLP-1 drugs, often find the skin does not follow. Searches for peptide creams and serums to tighten it have risen with the drugs. This page sets out what is known about the skin itself, what treatments have actually been tested in this population, and where peptides sit in that record. The short version: no randomized trial we could find has tested a topical peptide on loose skin after weight loss, and the literature that appears to link the two is mostly about the drugs. Nothing here is advice on treatment; a plastic surgeon or dermatologist can assess a particular case.
How this differs from ordinary "skin tightening"
Our page on peptides for skin tightening deals with laxity from ageing and the device trials attached to that word. Loose skin after large weight loss is a different condition: skin that was stretched for years over a larger body, often on the abdomen, arms, thighs and breasts as well as the face. It has its own surgical specialty (body contouring) and its own research literature, and the evidence from one should not be borrowed for the other. Injectable collagen stimulators are now marketed for the body too; what the studies and FDA reports show for one such use is on our page about the "Sculptra butt lift".
What happens to the skin
The clearest measurements come from skin removed during surgery. In a 2024 study, researchers examined 80 biopsies from abdominoplasties and breast reductions in people who had lost more than half their excess weight, 40 after bariatric surgery and 40 without it (Hany et al., Obesity Surgery, PMID 38277086). Collagen was reduced in both groups, with no significant difference between them. Elastic fibre content in abdominal skin was significantly lower in the bariatric group. Elastic fibre is the component that lets skin spring back; reduced and damaged fibre is the structural reason the skin stays loose.
How common the problem is has been measured by questionnaire. In a study of 57 people with a starting BMI above 50, most reported "a lot of" or "very much" excess skin a year after gastric bypass or duodenal switch, women more than men (Biörserud et al., 2014, PMID 24837559).
What has been tested
On 27 September 2026, a Europe PMC search of MEDLINE for loose, lax or excess skin together with weight loss or bariatric surgery returned 1,232 records. (PubMed's own search was unavailable that morning.) Seventeen carry the randomized-controlled-trial publication type. Read one by one, they study abdominoplasty techniques, helium-plasma skin tightening during surgery, exercise and nutrition programmes after bariatric surgery, therapeutic ultrasound, injectable fillers and unrelated outcomes that share the search words. None tests a topical peptide.
The trial that speaks most directly to non-surgical options is small and negative. Fourteen patients with excess upper-arm skin after bariatric surgery had one arm treated five times with therapeutic ultrasound and the other left as a control; arm volume, circumference and droop showed no statistical difference, although several patients reported feeling better (Bjerså et al., 2015, PMID 26155952). The authors' framing is worth quoting: "The only evidence-based treatment for excessive skin is plastic surgery."
The search trap: "peptide" in the drug's name
Adding peptide terms to the search above returned 178 records, which looks like a substantial peptide literature. It is not. The weight-loss drugs are glucagon-like peptide-1 receptor agonists, so any paper that names them matches the word "peptide". Excluding the drug names (glucagon-like peptide, GLP-1, semaglutide, tirzepatide, liraglutide) cut the count to 73, and reading the first twenty of those turned up cellulite cases, a plant-adaptogen serum, reviews of bariatric surgery and nutrition, and unrelated lab work. We found no topical-peptide trial for loose skin in any of them.
This is the same kind of trap this site has logged before: a search term that matches a string, not a substance. A reader who sees "178 studies on peptides and loose skin" has been told something false by a search box.
The one topical study in GLP-1 users
One study has tested a cream in this population. Thirty-three people in the Sacramento area who had lost weight rapidly, mainly on GLP-1 or GLP-1/GIP drugs, used the same "volumizing" cream for 12 weeks; 29 finished (Nguyen et al., Journal of Cosmetic Dermatology, 2026, PMID 41556403). The authors report wrinkle-severity scores down 20.7% at 12 weeks, ultrasound skin-plus-fat thickness up 20.1%, and firmness and elasticity up 22.5% and 23.2%.
Three features limit what it shows, and they are visible in the abstract:
- No comparison group. Everyone received the same cream, so the study cannot separate the cream from time, season, moisturising in general or the weight loss slowing down.
- A multi-active formula. The product's transcribed ingredient list on INCIDecoder (read 27 September 2026) includes a peptide at position 17 alongside bakuchiol, a vitamin C ester (tetrahexyldecyl ascorbate), ectoin, algae and plant extracts. Any effect belongs to the formula, not to one ingredient.
- The face only. The loose skin this page is about is mostly on the body.
It is a reasonable pilot. It is not evidence that peptides help loose skin.
What peptides have been tested for
Topical peptides have small trials on wrinkles and instrument-measured elasticity in ordinary ageing facial skin, collected on our peptides for wrinkles and what peptides do for skin pages. Oral collagen peptides have trials on elasticity too, covered on collagen peptides for hair and skin. None of those populations had lost large amounts of weight, and none measured the structural damage the biopsy studies describe. The distance from "elasticity readings moved in 40-year-old facial skin" to "tightens the abdomen after a 50 kg loss" is not one the evidence has covered.
What is not known
- Whether any topical ingredient, peptide or otherwise, changes loose skin after large weight loss in a vehicle-controlled trial.
- Whether skin after GLP-1 weight loss differs structurally from skin after bariatric or dietary weight loss. Early papers compare surgical outcomes, not biopsies.
- Whether the speed of loss matters for the skin, independent of the amount.
For the face specifically, GLP1 Ledger's page on Ozempic face covers what has been published about facial changes on the drugs. For excess body skin, the published treatments are surgical, and a plastic surgeon is the person to ask.